R. Coleman Lindsley

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation

  Journal of Clinical Oncology · 2026-06-25

• Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

  American Journal of Hematology · 2026-03-29

• Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing

  Leukemia · 2026-02-26

• Exposure to Agent Orange and association with myelodysplastic syndromes

  Blood Advances · 2026-02-24

• CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial

  Blood Advances · 2026-02-02 · 3 citations

• Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria

  Blood Advances · 2026-01-15

• Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML

  Blood Advances · 2025-12-05

• Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

  Bone Marrow Transplantation · 2025-11-24 · 2 citations

• Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDSPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-14

• MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy

  Clinical Chemistry · 2025-11-08 · 1 citations

• Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

  Blood · 2025-11-03 · 1 citations

• Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial

  Blood · 2025-11-03

• Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

  Blood · 2025-11-03

• Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

  Blood · 2025-11-03

• Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

  Blood · 2025-11-03

• Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

  Blood · 2025-11-03

• Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations

  Blood · 2025-11-03 · 4 citations

• Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

  Blood · 2025-11-03

• Prevalence and significance of cytoses in clonal hematpoiesis

  Blood · 2025-11-03

• A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

  Blood · 2025-11-03